Ginkgo Bioworks Holdings, Inc. provides horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its cell programs are designed to enable biological production of products as diverse as therapeutics, key food ingredients and chemicals derived from petroleum. Its Foundry segment consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two assets: the Foundry, biology lab facilities, enabled by investment in workflows, custom software, robotic automation, and data science and analytics. Its Biosecurity segment consists of COVID-19 testing products and services primarily provided to public health authorities. It also owns the adeno-associated virus capsid discovery and engineering platform assets.